Reinventing the fight against bacteria, one phage at a time.

Armata to advance bacteriophage therapy to phase 3 for S. aureus LOS ANGELES - Armata Pharmaceuticals, Inc. (NYSE American:ARMP) announced Tuesday that the FDA has agreed that data from its Phase 2a diSArm study support advancement of AP-SA02 to Phase 3 clinical testing for complicated Staphylococcus aureus bacteremia. The biotech company, currently valued at $238.47 million, has seen its stock surge over 230% in the past year, trading at $6.68 as investors react to its clinical progress. According to  InvestingPro  data, analysts maintain a Strong Buy consensus on the stock with price targets ranging from $9 to $15. The company plans to initiate the Phase 3 superiority study in the second half of 2026, following the FDA’s End-of-Phase 2 written response. The regulatory agency provided guidance on key elements of the study design, which will assess AP-SA02’s effectiveness compared to current standard of care treatments. "The completion of our Phase 2a diSArm was the first evid...

  $3.3M to Fund Trial of Ai-Designed Bacteriophage Therapy for HAP/VAP Locus Biosciences will conduct a clinical trial for its Ai-designed bacteriophage therapeutic for HAP/VAP caused by antibiotic-resistant P. aeruginosa. RT’s Three Key Takeaways: Federal support for phage therapy  – Locus Biosciences received a $3.3 million NIAID contract, with potential expansion to $28 million, to advance a Phase 1b clinical trial of its engineered bacteriophage LBP-PA01 for antibiotic-resistant  Pseudomonas aeruginosa  pneumonia. AI-designed precision antibacterial  – LBP-PA01 was developed using Locus’s AI- and robotics-driven platform, which rapidly designs and optimizes engineered bacteriophage cocktails to selectively kill drug-resistant bacteria. Addressing a critical public health threat  – The program targets hospital-acquired and ventilator-associated pneumonia, major ICU killers for which antibiotic-resistant  P. aeruginosa  is a CDC-designated ...